The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 58-66

  Duvic, Madeleine ^a   Dimopoulos, Meletios ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Clinical trial; HDAC; Hematologic malignancies; Histone deacetylase inhibitors; Safety; Vorinostat

Indexed keywords

BORTEZOMIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; QUISINOSTAT; ROMIDEPSIN; VORINOSTAT; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; HISTONE ACETYLTRANSFERASE; HYDROXAMIC ACID;

ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COUGHING; CUTANEOUS T CELL LYMPHOMA; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FATIGUE; FEVER; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; DISEASE MANAGEMENT; DRUG EFFECTS; HEMATOLOGIC DISEASE; METABOLISM; PATHOLOGY; PROTEIN FOLDING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DEPSIPEPTIDES; DISEASE MANAGEMENT; HEMATOLOGIC NEOPLASMS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; PROTEIN FOLDING; TREATMENT OUTCOME;

EID: 84962019062     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.04.003     Document Type: Review

References (63)

1. Lichtman M.A. Battling the hematological malignancies: the 200 years' war. Oncologist 2008, 13:126-138.
2. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009, 20:1293-1302.
3. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
4. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
5. Venner C.P., Connors J.M., Sutherland H.J., Shepherd J.D., Hamata L., Mourad Y.A., et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leuk Lymphoma 2011, 52:34-41.
6. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009, 15:5250-5257.
7. Mann B.S., Johnson J.R., He K., Sridhara R., Abraham S., Booth B.P., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007, 13:2318-2322.
8. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117:336-342.
9. Shao W., Growney J.D., Feng Y., O'Connor G., Pu M., Zhu W., et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer 2010, 127:2199-2208.
10. Subramanian M., Bates S.E., Wright J.J., Espinoza-Delgado I., Piekarz R.L. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010, 3:2751-2767.
11. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007, 74:659-671.
12. Jagannath S., Dimopoulos M.A., Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010, 34:1111-1118.
13. ZOLINZA (vorinostat) [prescribing information]. Merck & Co., Inc. Whitehouse Station, NJ, USA, 2011.
14. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
15. Duvic M., Olsen E.A., Breneman D., Pacheco T.R., Parker S., Vonderheid E.C., et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009, 9:412-416.
16. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
17. Alsayed Y., Nair B.P., Kauffman M., Petty N., Waheed S., Van Rhee F., et al. Carfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced and refractory multiple myeloma (FARMM). J Clin Oncol 2010, 28(Suppl. 15):e18504.
18. Crump M., Coiffier B., Jacobsen E.D., Sun L., Ricker J.L., Xie H., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19:964-969.
19. Dimopoulos M., Siegel D.S., Lonial S., Qi J., Hajek R., Facon T., et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013, 14:1129-1140.
20. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
21. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49:502-507.
22. Siegel D.S., McBride L., Bilotti E., Schmidt L., Gao Z., Tufail M., et al. Vorinostat overcomes lenalidomide-dexamethasone and lenalidomide-bortezomib-dexamethasone resistance in relapsed/refractory multiple myeloma. Blood 2010, 116(21):3065.
23. Siegel D.S., Dimopoulos M.A., Yoon S.S., Laubach J., Kaufman J., Goldschmidt H., et al. VANTAGE 095: Final results from a global, single-arm phase 2b trial of vorinstat in combination with bortezomib in salvage multiple myeloma patients. Haematologica 2012, 97(Suppl. 1):119.
24. Siegel D.S., Richardson P., Dimopoulos M., Moreau P., Mitsiades C., Weber D., et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 2014, 4:e202.
25. Voorhees P.M., Gasparetto C., Osman K., Richards K., Ferraro M., Garcia R., et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. Blood 2010, 1955.
26. Watanabe T., Kato H., Kobayashi Y., Yamasaki S., Morita-Hoshi Y., Yokoyama H., et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010, 101:196-200.
27. Weber D.M., Graef T., Hussein M., Sobecks R.M., Schiller G.J., Lupinacci L., et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012, 12:319-324.
28. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
29. Munster P.N., Rubin E.H., Van Belle S., Friedman E., Patterson J.K., Van Dyck K., et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009, 15:7077-7084.
30. Lynch D.R., Washam J.B., Newby L.K. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol J 2012, 19:434-438.
31. Cashen A., Juckett M., Jumonville A., Litzow M., Flynn P.J., Eckardt J., et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012, 91:33-38.
32. Piekarz R.L., Frye A.R., Wright J.J., Steinberg S.M., Liewehr D.J., Rosing D.R., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12:3762-3773.
33. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
34. Garcia-Manero G., Silverman L.B., Gojo I., Michaelis L., Parmar S., Goldberg S., et al. A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplatic syndromes: preliminary results. Blood 2008, 112(11):5084.
35. Ogura M., Ando K., Suzuki T., Ishizawa K., Oh S.Y., Itoh K., et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2014, 165:768-776.
36. Rubin E.H., Agrawal N.G., Friedman E.J., Scott P., Mazina K.E., Sun L., et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006, 12:7039-7045.
37. Kirschbaum M., Gojo I., Goldberg S.L., Bredeson C., Kujawski L.A., Yang A., et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol 2014, 167:185-193.
38. M. Ogura, K. Ando, K. Tobinai et al. A phase I study of vorinostat combined with bortezomib in patients with relapsed or refractory multiple myeloma. Annual Meeting of the Japanese Society of Hematology 2013; Sapporo City, Japan.
39. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010, 16:4094-4104.
40. Mitsiades C.S., Hideshima T., Chauhan D., McMillin D.W., Klippel S., Laubach J.P., et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009, 46:166-175.
41. Budde L.E., Zhang M.M., Shustov A.R., Pagel J.M., Gooley T.A., Oliveira G.R., et al. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol 2013, 161:183-191.
42. Dummer R., Beyer M., Hymes K., Epping M.T., Bernards R., Steinhoff M., et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma 2012, 53:1501-1508.
43. Hopfinger G., Nosslinger T., Lang A., Linkesch W., Melchardt T., Weiss L., et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol 2014, 93:459-462.
44. Oki Y., Younes A., Copeland A., Hagemeister F., Fayad L.E., McLaughlin P., et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 2013, 162:138-141.
45. Schmitt S., Ho A.D., Goldschmidt H. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie 2010, 33:183-186.
46. Wolf J.L., Siegel D., Goldschmidt H., Hazell K., Bourquelot P.M., Bengoudifa B.R., et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 53:1820-1823.
47. Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S.L., Kirschbaum M.H., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27:5410-5417.
48. ISTODAX® (romidepsin) [prescribing information]. Celgene. Summit, NJ, USA, 2012.
49. Coiffier B., Pro B., Prince H.M., Foss F., Sokol L., Greenwood M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30:631-636.
50. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
51. F. Child, P.O. Romero, R. Alvarez et al. Phase 2 multicenter trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously teated stage IB-IVA cutaneous T-cell lymphoma, 2012; 3676.
52. Harrison S.J., Quach H., Link E., Seymour J.F., Ritchie D.S., Ruell S., et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011, 118:6274-6283.
53. Offidani M., Polloni C., Cavallo F., Liberati A.M., Ballanti S., Pulini S., et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 53:1722-1727.
54. Richardson P.G., Alsina M., Weber D.M., Coutre S.E., Lonial S., Gasparetto C., et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Blood 2011, 118(21):814.
55. San Miguel J.F., Richardson P.G., Gunther A., Sezer O., Siegel D., Blade J., et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013, 31:3696-3703.
56. Sullivan D., Singhal S., Schuster M., Berenson J., Gimsing P., Wislöff F., et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 2006, 108(11):3583.
57. Bishton M.J., Harrison S.J., Martin B.P., McLaughlin N., James C., Josefsson E.C., et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117:3658-3668.
58. Giver C.R., Jaye D.L., Waller E.K., Kaufman J.L., Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 2011, 25:362-365.
59. Iancu-Rubin C., Gajzer D., Mosoyan G., Feller F., Mascarenhas J., Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 2012, 40:564-574.
60. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
61. Camacho L.H., Olson J., Tong W.P., Young C.W., Spriggs D.R., Malkin M.G. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007, 25:131-138.
62. Galanis E., Jaeckle K.A., Maurer M.J., Reid J.M., Ames M.M., Hardwick J.S., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009, 27:2052-2058.
63. Whitehead R.P., Rankin C., Hoff P.M., Gold P.J., Billingsley K.G., Chapman R.A., et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2009, 27:469-475.